# Efficacy and Safety of Ciclesonide (CIC) Administered Twice Daily in Pediatric Patients With Asthma.

> **NCT00392288** · PHASE3 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 528 (actual)

## Conditions studied

- Asthma

## Interventions

- **DRUG:** Ciclesonide
- **DRUG:** Ciclesonide
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00392288
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-09
- **Primary completion:** 2008-02
- **Final completion:** 2008-02
- **Target enrollment:** 528 (ACTUAL)
- **Last updated:** 2017-02-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00392288

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00392288, "Efficacy and Safety of Ciclesonide (CIC) Administered Twice Daily in Pediatric Patients With Asthma.". Retrieved via AI Analytics 2026-06-10 from https://api.ai-analytics.org/clinical/NCT00392288. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*